TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Treatment rates for bacterial vaginosis and trichomoniasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Concentrations of MMP‐1, MMP‐2, MMP‐3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of IFN‐alpha2, IFN‐beta, IFN‐gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral dorsalis pedis pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mothers' willingness to participate again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mothers' recommendation to family and friends
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mothers' satisfaction with the trial experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response to vardenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage transfused
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MNA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac specific cell damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of big-Endothelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N9 SEP latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MEP latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occlusion adjustment needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal marginal discrepancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: point abstinence from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: II EF-5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corus Spongiosum PSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in inflamed lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in non-inflamed lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall grade reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Seroconversion to protective antibody levels against hepatitis A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rise in neutralizing antibody levels against typhoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum neutralizing antibody against yellow fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis of pseudoallergen-induced urticaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment probability based on NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of circulating Tie2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prediction of progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent with glucose in target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean overnight glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Episodes of nocturnal hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: MSNA (Muscle Sympathetic Nerve Activity) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowest SaO2 during the 6-min walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum KL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ground-glass score on high-resolution CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycemic control (higher A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: P3 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P3 latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of A (H1N1) influenza
Endpoint domain: Mortality/survival
Primary endpoint: serum concentrations of TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of infant sleep problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPDS scores indicating depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF-12 mental health scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Constipation symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Grade 3 or higher treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: mean MGI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean GBI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participant quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: levels of angiotensin-(1-7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Length of root canal fillings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilization of the blood-aqueous barrier (BAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTDIvol and DLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average alertness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean Vco2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive tasks performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Net clinical benefit (death, nonfatal MI, or nonfatal major bleeding)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in PPT-8 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to rewarm to 36.5 degrees C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of core temperature increase after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejaculation controllability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature Ejaculation Diagnostic Tool scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants losing at least 5% of baseline body weight at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC evaluation form scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal epithelial defect percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative ocular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low density lipoprotein cholesterol change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum creatinine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: fasting glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of lower extremity venous insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pro-alphaC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Spermatogenesis restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity (total glucose disposal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness and safety of nizatidine compared to ranitidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Development of HAPI of the heels
Endpoint domain: Adverse events/effects
Primary endpoint: Goniometric scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: improvement in attention/executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in memory domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in psychological well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Withdrawal rate due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Epithelial defect resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive correction within +/- 0.5 diopter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean HAM-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D responder analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opiate analgesia required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sick leave duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VRS scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Recurrence of DME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of DME absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of additional treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: societal costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: community living skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total symptom score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peak flow rates improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postvoiding residual volume improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in emotional abuse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Student competency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLE experience rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lowering of periodontal pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lutein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean antibody concentration after three doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in overall pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance stability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional capacity stability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time on vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days on mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fractional anisotropy values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: placebo-adjusted magnitude of effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score during transrectal prostate biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinically significant PPCs
Endpoint domain: Adverse events/effects
Primary endpoint: IFN‐γ cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Strength gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VPS (Visual Analog Scale for Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total response rate to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ALT and ALB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myostatin mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: myogenin mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total body muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean DFT (Defibrillation Threshold)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of oesophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in the burden of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in maximum bladder capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of episodes of nocturia in 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocturnal urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and disturbance level of nocturnal behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity (OGIS index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin secretion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tear clearance time (T 1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear secretion (Schirmer-1 value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface staining (rose bengal staining value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in HAM-A6 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature Infant Pain Profile scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in systolic and diastolic pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total syndrome score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cuspal deflection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal seal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shock and death anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: body image concerns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of CMPI patients who became CM-tolerant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIEF-5 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Four-week success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prostate cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in daily incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Backswing hip turn (BSHT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD(75) shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle/brachial pulse indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lost contact with treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inpatient service-use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: chair rise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height standard deviation score (HSDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: net increase in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: time to exceed upper normal IOP value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Adrenaline response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EV reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %REV reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jaw-opening pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chewing pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vestibular disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced annual medical care charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive values for NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sampling discordance for portal fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline of the glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: End stage renal failure
Endpoint domain: Mortality/survival
Primary endpoint: Transient hypocalcemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Vocal fold paralysis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HeartCheck score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening uptake as a proportion of total eligible women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinic-measured blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of crow's feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of high frequency to total power of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ratio of low to high frequency power of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of retinopathy progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of microalbuminuria or AER>40mg/24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes